U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H14O5
Molecular Weight 274.2687
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of METHYSTICIN

SMILES

COC1=CC(=O)O[C@H](C1)\C=C\C2=CC=C3OCOC3=C2

InChI

InChIKey=GTEXBOVBADJOQH-FWEMWIAWSA-N
InChI=1S/C15H14O5/c1-17-12-7-11(20-15(16)8-12)4-2-10-3-5-13-14(6-10)19-9-18-13/h2-6,8,11H,7,9H2,1H3/b4-2+/t11-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H14O5
Molecular Weight 274.2687
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 1
Optical Activity UNSPECIFIED

Methysticin is a kavalactone originally found in Piper methysticum (kava plant). Methysticin exhibits neuroprotective, neuromodulatory, and antifungal activities. Methysticin may also display anti-inflammatory benefit, inhibiting activation of NF-κB in lung adenocarcinoma tissue. Methysticin activates Nrf2 in neurons and astroglia, protecting against amyloid-β (Aβ)-induced neurotoxicity. This compound displays antimicrobial efficacy against species of Fusarium, Trichoderma, and Colletotrichum. Additionally, methysticin inhibits peak amplitude of voltage-gated Na+ channels in hippocampal neurons. Methysticin administration activates the Nrf2 pathway and reduces neuroinflammation, hippocampal oxidative damage and memory loss in a mouse model of AD. Therefore, kavalactones might be suitable candidates to serve as lead compounds for the development of a new class of neuroprotective drugs.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro.
2005 Oct
Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1.
2011 Dec
Patents

Sample Use Guides

Mice: Treatment of transgenic APP/Psen1 mice (n=6) was started at an age of 25 weeks and lasted for 27 weeks. The animals were treated once a week with 6 mg/kg bodyweight methysticin.
Route of Administration: Oral
In Vitro Use Guide
In a concentration-range from 10 to 100 uM methysticin reversibly blocked epileptiform activity in in vitro rat seizure models.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:10:42 GMT 2023
Edited
by admin
on Fri Dec 15 19:10:42 GMT 2023
Record UNII
M832AIJ6HX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYSTICIN
MI  
Common Name English
KAVATIN
Common Name English
KAVAHIN
Common Name English
(6R)-6-((1E)-2-(1,3-BENZODIOXOL-5-YL)ETHENYL)-5,6-DIHYDRO-4-METHOXY-2H-PYRAN-2-ONE
Systematic Name English
NSC-112158
Code English
METHYSTICIN [MI]
Common Name English
6-(3',4'-METHYLENEDIOXYSTYRYL)-4-METHOXY-5,6-DIHYDRO-2H-PYRAN-2-ONE
Common Name English
Classification Tree Code System Code
DSLD 2592 (Number of products:13)
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
Code System Code Type Description
MERCK INDEX
m7484
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5033674
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
MESH
C076881
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
PUBCHEM
5281567
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
CAS
495-85-2
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
WIKIPEDIA
METHYSTICIN
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
NSC
112158
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
FDA UNII
M832AIJ6HX
Created by admin on Fri Dec 15 19:10:42 GMT 2023 , Edited by admin on Fri Dec 15 19:10:42 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT